Logo do repositório
 
Publicação

Immune-monitoring of myelodysplastic neoplasms: recommendations from the i4MDS consortium

2024-05Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authori4MDS consortium
dc.contributor.authorTentori, Cristina A.
dc.contributor.authorZhao, Lin P.
dc.contributor.authorTinterri, Benedetta
dc.contributor.authorStrange, Kathryn E.
dc.contributor.authorZoldan, Katharina
dc.contributor.authorDimopoulos, Konstantinos
dc.contributor.authorFeng, Xingmin
dc.contributor.authorRiva, Elena
dc.contributor.authorLim, Benjamin
dc.contributor.authorSimoni, Yannick
dc.contributor.authorMurthy, Vidhya
dc.contributor.authorHayes, Madeline J.
dc.contributor.authorPoloni, Antonella
dc.contributor.authorPadron, Eric
dc.contributor.authorCardoso, Bruno A.
dc.contributor.authorCross, Michael
dc.contributor.authorWinter, Susann
dc.contributor.authorSantaolalla, Aida
dc.contributor.authorPatel, Bhavisha A.
dc.contributor.authorGroarke, Emma M.
dc.contributor.authorWiseman, Daniel H.
dc.contributor.authorJones, Katy
dc.contributor.authorJamieson, Lauren
dc.contributor.authorManogaran, Charles
dc.contributor.authorDaver, Naval
dc.contributor.authorGallur, Laura
dc.contributor.authorIngram, Wendy
dc.contributor.authorFerrell, P. Brent
dc.contributor.authorSockel, Katja
dc.contributor.authorDulphy, Nicolas
dc.contributor.authorChapuis, Nicolas
dc.contributor.authorKubasch, Anne S.
dc.contributor.authorOlsnes, Astrid M.
dc.contributor.authorKulasekararaj, Austin
dc.contributor.authorLavellade, Hugues De
dc.contributor.authorKern, Wolfgang
dc.contributor.authorHemelrijck, Mieke Van
dc.contributor.authorBonnet, Dominique
dc.contributor.authorWesters, Theresia M.
dc.contributor.authorFreeman, Sylvie
dc.contributor.authorOelschlaegel, Uta
dc.contributor.authorValcarcel, David
dc.contributor.authorRaddi, Marco G.
dc.contributor.authorGrønbæk, Kirsten
dc.contributor.authorFontenay, Michaela
dc.contributor.authorLoghavi, Sanam
dc.contributor.authorSantini, Valeria
dc.contributor.authorAlmeida, Antonio M.
dc.contributor.authorIrish, Jonathan M.
dc.contributor.authorSallman, David A.
dc.contributor.authorYoung, Neal S.
dc.contributor.authorLoosdrecht, Arjan A. van de
dc.contributor.authorAdès, Lionel
dc.contributor.authorPorta, Matteo G. Della
dc.contributor.authorCargo, Catherine
dc.contributor.authorPlatzbecker, Uwe
dc.contributor.authorKordasti, Shahram
dc.date.accessioned2024-06-18T14:39:40Z
dc.date.available2024-06-18T14:39:40Z
dc.date.issued2024-05
dc.description.abstractAdvancements in comprehending myelodysplastic neoplasms (MDS) have unfolded significantly in recent years, elucidating a myriad of cellular and molecular underpinnings integral to disease progression. While molecular inclusions into prognostic models have substantively advanced risk stratification, recent revelations have emphasized the pivotal role of immune dysregulation within the bone marrow milieu during MDS evolution. Nonetheless, immunotherapy for MDS has not experienced breakthroughs seen in other malignancies, partly attributable to the absence of an immune classification that could stratify patients toward optimally targeted immunotherapeutic approaches. A pivotal obstacle to establishing “immune classes” among MDS patients is the absence of validated accepted immune panels suitable for routine application in clinical laboratories. In response, we formed International Integrative Innovative Immunology for MDS (i4MDS), a consortium of multidisciplinary experts, and created the following recommendations for standardized methodologies to monitor immune responses in MDS. A central goal of i4MDS is the development of an immune score that could be incorporated into current clinical risk stratification models. This position paper first consolidates current knowledge on MDS immunology. Subsequently, in collaboration with clinical and laboratory specialists, we introduce flow cytometry panels and cytokine assays, meticulously devised for clinical laboratories, aiming to monitor the immune status of MDS patients, evaluating both immune fitness and identifying potential immune “risk factors.” By amalgamating this immunological characterization data and molecular data, we aim to enhance patient stratification, identify predictive markers for treatment responsiveness, and accelerate the development of systems immunology tools and innovative immunotherapies.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10.1002/hem3.64pt_PT
dc.identifier.eid85193350223
dc.identifier.issn2572-9241
dc.identifier.pmid38756352
dc.identifier.urihttp://hdl.handle.net/10400.14/45517
dc.identifier.wos001223138800001
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.titleImmune-monitoring of myelodysplastic neoplasms: recommendations from the i4MDS consortiumpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue5pt_PT
oaire.citation.titleHemaSpherept_PT
oaire.citation.volume8pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
99177854.pdf
Tamanho:
1.6 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
3.44 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

CIIS - Contribuições em Revistas Científicas / Contribution to Journals